000			02308cam a2200325 a 4500
003			EG-GiCUC
008			160929s2016 ua f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.19.05.M.Sc.2016.Af.M
100	0		_aAfaf Mohammad Mahmoud
245	1	0	_aMicafungin as a prophylactic antifungal during induction phase of chemotherapy for pediatric acute lymphoblastic leukemia / _cAfaf Mohammad Mahmoud ; Supervised Lobna Mohamed Shalaby , Hadir Ahmad Elmahallawy , Sahar Ahmad Khalil
246	1	5	_aللوقاية من الاصابة بالفطريات خلال الفترة التحفيزية من علاج سرطان الدم الليمفاوى الحاد فى الاطفال Micafungin استخدام عقار المايكافنجين
260			_aCairo : _bAfaf Mohammad Mahmoud , _c2016
300			_a89 P. ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Pediatric Oncology
520			_aBackground: Invasive fungal infection (IFI) remains a major cause of infectious morbidity and mortality in neutropenic patients receiving chemotherapy or hematopoietic stem cell transplantation (HSCT). Micafungin exhibits broad antifungal activity against both Aspergillus and Candida species. Objective: We performed a prospective study to determine the efficacy, safety, and tolerability of prophylactic micafungin against IFI in pediatric neutropenic patients during induction chemotherapy for acute lymphoblastic leukemia (ALL). Results: Treatment success rate, defined as absence of proven, probable, or possible IFIs, was 75%. No adverse events were observed that could be related to micafungin prophylaxis. Conclusions: These results suggest that prophylactic micafungin is well tolerated and may prevent IFIs in pediatric patients with neutropenia receiving chemotherapy
530			_aIssued also as CD
653		4	_aALL
653		4	_aInduction chemotherapy
653		4	_aPediatric
700	0		_aHadir Ahmad Elmahallawy , _eSupervisor
700	0		_aLobna Mohamed Shalaby , _eSupervisor
700	0		_aSahar Ahmad Khalil , _eSupervisor
905			_aNazla _eRevisor
905			_aSoheir _eCataloger
942			_2ddc _cTH
999			_c57886 _d57886